Literature DB >> 15371417

The heparin binding properties of heparin cofactor II suggest an antithrombin-like activation mechanism.

Denis O'Keeffe1, Steven T Olson, Nijole Gasiunas, John Gallagher, Trevor P Baglin, James A Huntington.   

Abstract

The serpin heparin cofactor II (HCII) is a glycosaminoglycan-activated inhibitor of thrombin that circulates at a high concentration in the blood. The antithrombotic effect of heparin, however, is due primarily to the specific interaction of a fraction of heparin chains with the related serpin antithrombin (AT). What currently prevents selective therapeutic activation of HCII is the lack of knowledge of the determinants of glycosaminoglycan binding specificity. In this report we investigate the heparin binding properties of HCII and conclude that binding is nonspecific with a minimal heparin length of 13 monosaccharide units required and affinity critically dependent on ionic strength. Rapid kinetics of heparin binding indicate an induced fit mechanism that involves a conformational change in HCII. Thus, HCII binds to heparin in a manner analogous to the interaction of AT with low affinity heparin. A fully allosteric 2000-fold heparin activation of thrombin inhibition by HCII is demonstrated for heparin chains up to 26 monosaccharide units in length. We conclude that the heparin-binding mechanism of HCII is closely analogous to that of AT and that the induced fit mechanism suggests the potential design or discovery of specific HCII agonists.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15371417     DOI: 10.1074/jbc.M408774200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

Review 1.  Molecular engineering of glycosaminoglycan chemistry for biomolecule delivery.

Authors:  Tobias Miller; Melissa C Goude; Todd C McDevitt; Johnna S Temenoff
Journal:  Acta Biomater       Date:  2013-10-09       Impact factor: 8.947

Review 2.  Approaches to prevent bleeding associated with anticoagulants: current status and recent developments.

Authors:  Manu Thomas Kalathottukaren; Charles A Haynes; Jayachandran N Kizhakkedathu
Journal:  Drug Deliv Transl Res       Date:  2018-08       Impact factor: 4.617

3.  Targeted inhibition of thrombin attenuates murine neonatal necrotizing enterocolitis.

Authors:  Kopperuncholan Namachivayam; Krishnan MohanKumar; Darla R Shores; Sunil K Jain; Jennifer Fundora; Allen D Everett; Ling He; Hua Pan; Samuel A Wickline; Akhil Maheshwari
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-04       Impact factor: 11.205

4.  Glycosaminoglycan-binding properties and kinetic characterization of human heparin cofactor II expressed in Escherichia coli.

Authors:  Suryakala Sarilla; Sally Y Habib; Douglas M Tollefsen; David B Friedman; Diana R Arnett; Ingrid M Verhamme
Journal:  Anal Biochem       Date:  2010-07-27       Impact factor: 3.365

5.  Fluorescent reporters of thrombin, heparin cofactor II, and heparin binding in a ternary complex.

Authors:  Ingrid M Verhamme
Journal:  Anal Biochem       Date:  2011-12-06       Impact factor: 3.365

Review 6.  Revisiting the Pharmacology of Unfractionated Heparin.

Authors:  Abdallah Derbalah; Stephen Duffull; Fiona Newall; Katie Moynihan; Hesham Al-Sallami
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

7.  Synthetic glycopolymers and natural fucoidans cause human platelet aggregation via PEAR1 and GPIbα.

Authors:  Caroline Kardeby; Knut Fälker; Elizabeth J Haining; Maarten Criel; Madelene Lindkvist; Ruben Barroso; Peter Påhlsson; Liza U Ljungberg; Mattias Tengdelius; G Ed Rainger; Stephanie Watson; Johannes A Eble; Marc F Hoylaerts; Jonas Emsley; Peter Konradsson; Steve P Watson; Yi Sun; Magnus Grenegård
Journal:  Blood Adv       Date:  2019-02-12

8.  Sucrose octasulfate selectively accelerates thrombin inactivation by heparin cofactor II.

Authors:  Suryakala Sarilla; Sally Y Habib; Dmitri V Kravtsov; Anton Matafonov; David Gailani; Ingrid M Verhamme
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

9.  Cooperative heparin-mediated oligomerization of fibroblast growth factor-1 (FGF1) precedes recruitment of FGFR2 to ternary complexes.

Authors:  Alan Brown; Christopher J Robinson; John T Gallagher; Tom L Blundell
Journal:  Biophys J       Date:  2013-04-16       Impact factor: 4.033

10.  Heparin Binds Lamprey Angiotensinogen and Promotes Thrombin Inhibition through a Template Mechanism.

Authors:  Hudie Wei; Haiyan Cai; Jiawei Wu; Zhenquan Wei; Fei Zhang; Xin Huang; Lina Ma; Lingling Feng; Ruoxi Zhang; Yunjie Wang; Hermann Ragg; Ying Zheng; Aiwu Zhou
Journal:  J Biol Chem       Date:  2016-09-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.